Just before the market closed UBS put out a research note upgrading them to a buy., saying $6.50 can be justified on a break up basis.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025